Orlistat in the treatment of NASH: A case series

American Journal of Gastroenterology

Volumn 98, Issue 4, 2003, Pages 926-930

  Harrison, Stephen A ^b   Ramrakhiani, Sanjay ^b   Brunt, Elizabeth M ^b   Anbari, Maan A ^b   Cortese, Cherise ^b   Bacon, Bruce R ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TETRAHYDROLIPSTATIN;

ABDOMINAL DISTENSION; ADULT; ARTICLE; CASE REPORT; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER BIOPSY; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; OBESITY; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 0038630907     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07375.x     Document Type: Article

References (27)

1. Westwater JO, Fainer D. Liver impairment in the obese. Gastroenterology 1958;34:686-93.
2. Peters RL, Gay T, Reynolds TB. Post-jejunoileal bypass hepatic disease. Its similarity to alcoholic hepatic disease. Am J Clin Pathol 1975;63:318-31.
3. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
4. Harrison SA, Diehl AM. Fat and the liver - A molecular overview. Semin Gastroenterol Dis 2002;13:3-16.
5. Shimada M, Hashimoto E, Taniai M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2002;37:154-60.
6. Bugianesi E, Leone N, Vanni G, et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123:134-40.
7. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 2002;123:375-8.
8. Marchesini G, Brizi M, Marsell-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-5.
9. Sanyal AJ, Campbell-Sangert C, Mirshahi F, et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
10. Pagano G, Pacini G, Musso G, et al. Non-alcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology 2002;35: 367-72.
11. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with insulin resistance syndrome. Hepatology 2002;35: 373-9.
12. Marceau P, Iron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-7.
13. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99:1408-13.
14. Rozental P, Biava C, Spencer H, et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967;12:198-208.
15. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N Engl J Med 1970;282:829-34.
16. Ueno T, Sagawara H, Sujaka K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997:27;103-7.
17. Anderson T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol 1991;12:224-9.
18. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: A proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999:94;2467-71.
19. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
20. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
21. Harrison SA, Torgerson S, Hayashi P. Natural history of NASH: A clinical histopathologic study. Gastroenterology 2002;122:A-621(1) (abstract).
22. Kopelman PG. Obesity as a medical problem. Nature 2000; 404:635-43.
23. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U. S. Diabetes Care 2001; 24:1936-40.
24. Caldwell SH, Hespenheide EE, Redick JA, et al. A pilot study of a thiozolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-25.
25. Marchesini G, Brizi M, Giampaolo B, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4.
26. Neuschwander-Tetri BA, Sponseller C, Hampton KK, et al. Rosiglitazone improves insulin sensitivity, ALT and hepatic steatosis in patients with nonalcoholic steatohepatitis. Gastroenterology 2002;122:A-622 (abstract).
27. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000;20:270-9.